STAAR Surgical Company has formally appointed Warren Foust as President and Chief Executive Officer, effective August 4, 2026, with an annual base salary of $730,000 and equity awards tied to stock price targets reaching $100 per share. This move aims to stabilize leadership and directly align executive incentives with significant shareholder value creation, crucial for investors monitoring the company's long-term performance.
Key Highlights
- Warren Foust appointed President and CEO of STAAR Surgical Company, effective August 4, 2026.
- Foust's compensation includes a $730,000 annual base salary and performance-based options targeting $50, $75, and $100 per share.
- Deborah Andrews transitions to Executive Vice President while continuing as Chief Financial Officer.
STAAR Surgical Company (NASDAQ: STAA) has elevated Warren Foust to President and Chief Executive Officer, solidifying its leadership structure with a compensation package heavily weighted toward share price performance. Foust, who had been serving as Interim Co-CEO, assumes the permanent role effective August 4, 2026, with an annual base salary set at $730,000. This appointment, a key step in stabilizing the company's executive team, introduces a strong incentive for Foust to drive growth, aligning his interests directly with significant gains for STAAR Surgical shareholders through stock price hurdles up to $100 per share.
Foust Confirmed as Leader
Warren Foust's confirmation as CEO follows a tenure marked by progressive leadership roles within STAAR Surgical, having first joined as Chief Operating Officer in April 2023. He later served as President and COO from March 2025, then as Interim Co-CEO alongside Deborah Andrews since February 2026. Prior to joining STAAR, Foust held the position of Worldwide President for Johnson & Johnson Vision, Surgical, starting in December 2019, bringing substantial industry experience to his new post.
This latest executive change marks the 16th officer or director change disclosure for STAAR Surgical since August 2022, underscoring a period of notable leadership flux for the ophthalmic device maker. Investors will watch for signs that this appointment signals a more consistent strategic direction.
Performance-Linked Compensation Structure
Foust's new compensation plan includes an annual base salary of $730,000, paid bi-weekly at $28,076.92. His target annual cash bonus for fiscal 2026 will be calculated as 70% of his base salary earned from the start of fiscal 2026 through January 31, 2026, and then 100% of his base salary earned from February 1, 2026, for the remainder of the year. For fiscal year 2027 and beyond, his target bonus will be 100% of his annual base salary, reflecting a substantial incentive for achieving corporate goals.
This structure ensures a strong connection between executive reward and the company's market valuation, influencing long-term investment viability.
Equity Incentives and Market Context
The CEO grant to Foust includes 22,493 time-vesting RSUs, 40,471 time-vesting options, and 131,830 performance-vesting options. An additional 2027 grant will comprise 44,986 time-vesting RSUs, 80,942 time-vesting options, and 263,664 performance-vesting options, with these 2027 options split into two portions. The initial portion for 2027 includes 37,962 time-vesting and 123,659 performance-vesting options, followed by a second portion of 42,980 time-vesting and 140,005 performance-vesting options.
The market capitalization stands at approximately $1.1 billion, and shares have traded between $15.59 and $35.87 over the past 52 weeks, indicating significant volatility that new leadership will need to address to achieve the ambitious stock price targets. The company's short interest stands at 10% of shares outstanding, representing 7.7 days of average volume to cover as of July 15, 2026, suggesting some investors remain skeptical of its near-term prospects.
Future Leadership and Next Steps
In conjunction with Foust's promotion, Deborah Andrews will transition from Interim Co-CEO to Executive Vice President, continuing in her critical role as Chief Financial Officer. Her adjusted compensation package includes an option grant for up to 8,952 shares, a performance-based option grant for up to 29,159 shares, and an RSU award for 4,975 shares. The remaining equity awards for Foust and Andrews, including RSUs, are scheduled for grant on January 4, 2027.
Investors will closely monitor the upcoming second-quarter earnings report, which will provide the specific timing for a substantial portion of Foust's equity incentives and potentially offer further insights into the company's strategic outlook under its new permanent CEO.
Peers Moving on This News
- DENTSPLY SIRONA Inc (XRAY) down 2.9%
- Neogen Corp (NEOG) down 1.2%
- UFP Technologies Inc (UFPT) down 1.9%
Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...